Comparing Ascites Relief In Two Standard Treatments: Large Volume Paracentesis Vs. Early Tips Using Viatorr Controlled Expansion Stents
Primary Purpose
Hypertension, Portal, Ascites
Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Gore® Viatorr® Endoprosthesis with controlled expansion
Large Volume Paracentesis with albumin infusion
Sponsored by
About this trial
This is an interventional treatment trial for Hypertension, Portal focused on measuring end-stage liver disease, hepatic encephalopathy, cirrhosis
Eligibility Criteria
Inclusion Criteria:
- Males and females > 18 years of age at time of procedure
- First de novo TIPS placement
- Patent internal or external jugular vein
- Willing to provide the hepatology service information for follow up
- No known diagnosis of hypercoagulopathy
- No portal vein thrombosis
- No malignancy (must be a definite diagnosis)
- Patient must provide written informed consent
Proper clinical indication of TIPS based on American Association for the Study of Liver Diseases (AASLD) guidelines
- Recurrent ascites necessitating at least 2 large volume paracenteses performed within a minimum interval of 3 weeks
Exclusion Criteria:
- Age <18
- LVP > 6 times in 2 months
- Liver failure (Child Pugh > 12)
- Cardiac failure
- No right jugular venous access
- Absolute TIPS contraindications (e.g. right heart failure, severe encephalopathy, liver failure, pregnant (if possible)).
Sites / Locations
- UCLA Medical CenterRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Group A
Group B
Arm Description
Routine Large Volume Paracentesis (LVP) with albumin infusion
Early Transjugular intrahepatic portosystemic shunt (TIPS) procedure using Gore Viatorr CX
Outcomes
Primary Outcome Measures
Number of Paracentesis
The average number of paracentesis per week.
Secondary Outcome Measures
Transplant free survival
Overall survival without transplant after the treatment
Full Information
NCT ID
NCT04315571
First Posted
March 9, 2020
Last Updated
May 11, 2023
Sponsor
University of California, Los Angeles
Collaborators
W.L.Gore & Associates
1. Study Identification
Unique Protocol Identification Number
NCT04315571
Brief Title
Comparing Ascites Relief In Two Standard Treatments: Large Volume Paracentesis Vs. Early Tips Using Viatorr Controlled Expansion Stents
Official Title
Effective Ascites ReLief In earlY TIPS (EARLY TIPS) Using Viatorr CX vs. LVP Study
Study Type
Interventional
2. Study Status
Record Verification Date
May 2023
Overall Recruitment Status
Recruiting
Study Start Date
March 24, 2020 (Actual)
Primary Completion Date
January 1, 2024 (Anticipated)
Study Completion Date
January 1, 2026 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of California, Los Angeles
Collaborators
W.L.Gore & Associates
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No
5. Study Description
Brief Summary
For this study, the investigators will be collecting data based on patients' random selection to two different approved standard of care treatments for ascites: Subjects will get randomized into either Group A: Large Volume Paracentesis (LVP) with albumin infusion, or Group B: an early transjugular intrahepatic portosystemic shunt (TIPS) procedure.
Detailed Description
End Stage Liver Disease (ESLD) severely impacts body function leading to elevated blood pressure within the liver called "portal hypertension." One of its subsequent symptoms is ascites, or fluid accumulation in the abdomen. One standard treatment to relieve ascites is large volume paracentesis (puncture of the abdomen to drain the fluid). Another standard treatment is the TIPS procedure, which involves creating a shunt (small passage allowing fluid movement) within the liver to relieve the increased blood pressure in the liver.
For this study, the investigators will be collecting data based on patients' random selection to two different approved standard of care treatments for ascites: Subjects will get randomized into either Group A: Large Volume Paracentesis (LVP) with albumin infusion, or Group B: an early transjugular intrahepatic portosystemic shunt (TIPS) procedure.
The study will include about 68 patients (34 patients will be selected for Group A: continuing conservative treatment of LVP with albumin infusion, and 34 patients will be selected for Group B: undergoing early TIPS with Gore®Viatorr®CX). Each patient will be followed up at 1 month, 3 months, 6 months, and 12 months.
The primary objective of this study is to evaluate the overall clinical efficacy in symptom relief of ascites of patients receiving the Gore® Viatorr® CX in early TIPS procedures compared to LVP (large volume paracenthesis). In order to so, the investigators will be using information found in patient medical records, collected as a part of standard of care, to analyze clinical outcomes, complications, and the rate of secondary interventions at follow-up.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension, Portal, Ascites
Keywords
end-stage liver disease, hepatic encephalopathy, cirrhosis
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
68 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Group A
Arm Type
Active Comparator
Arm Description
Routine Large Volume Paracentesis (LVP) with albumin infusion
Arm Title
Group B
Arm Type
Active Comparator
Arm Description
Early Transjugular intrahepatic portosystemic shunt (TIPS) procedure using Gore Viatorr CX
Intervention Type
Device
Intervention Name(s)
Gore® Viatorr® Endoprosthesis with controlled expansion
Other Intervention Name(s)
TIPS
Intervention Description
TIPS (Transjugular Intrahepatic Portosystemic Shunt) is a minimally invasive procedure in which a new path is made through the liver to carry blood from the portal vein to the heart, thus helping to alleviate the problems associated with elevated portal vein pressure.
Intervention Type
Procedure
Intervention Name(s)
Large Volume Paracentesis with albumin infusion
Other Intervention Name(s)
LVP with albumin infusion
Intervention Description
For therapeutic (large-volume) paracentesis, a 14-gauge cannula attached to a vacuum aspiration system is used to collect up to 8 L of ascitic fluid. Concurrent infusion of IV albumin is recommended during large-volume paracentesis to help avoid significant intravascular volume shift and postprocedural hypotension.
Primary Outcome Measure Information:
Title
Number of Paracentesis
Description
The average number of paracentesis per week.
Time Frame
1 year post-procedure
Secondary Outcome Measure Information:
Title
Transplant free survival
Description
Overall survival without transplant after the treatment
Time Frame
1 year post-procedure or until the patient expires or receives transplant
Other Pre-specified Outcome Measures:
Title
Stent diameter change
Description
Stent diameter changes from the time of TIPS placement
Time Frame
1 month and 6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Males and females > 18 years of age at time of procedure
First de novo TIPS placement
Patent internal or external jugular vein
Willing to provide the hepatology service information for follow up
No known diagnosis of hypercoagulopathy
No portal vein thrombosis
No malignancy (must be a definite diagnosis)
Patient must provide written informed consent
Proper clinical indication of TIPS based on American Association for the Study of Liver Diseases (AASLD) guidelines
Recurrent ascites necessitating at least 2 large volume paracenteses performed within a minimum interval of 3 weeks
Exclusion Criteria:
Age <18
LVP > 6 times in 2 months
Liver failure (Child Pugh > 12)
Cardiac failure
No right jugular venous access
Absolute TIPS contraindications (e.g. right heart failure, severe encephalopathy, liver failure, pregnant (if possible)).
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Saima C Chaabane, PhD
Phone
4244654482
Email
schaabane@mednet.ucla.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Saima Chaabane
Phone
3107948995
Email
schaabane@mednet.ucla.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Edward W Lee, MD, PhD
Organizational Affiliation
University of California
Official's Role
Principal Investigator
Facility Information:
Facility Name
UCLA Medical Center
City
Los Angeles
State/Province
California
ZIP/Postal Code
90095
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Edward W Lee, M.D.
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Comparing Ascites Relief In Two Standard Treatments: Large Volume Paracentesis Vs. Early Tips Using Viatorr Controlled Expansion Stents
We'll reach out to this number within 24 hrs